J Blahova Dusankova1, T Kalincik, T Dolezal, G Kobelt, E Havrdova. 1. Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1 Faculty of Medicine and General University Hospital in Prague, Czech Republic. blahova.dusankova@gmail.com
Abstract
BACKGROUND: Information about cost of multiple sclerosis (MS) is available from a number of European countries, but no data from the Czech Republic have been published so far. OBJECTIVE: The objective of this study was to establish the cost of MS in the Czech Republic, overall and by level of disease severity. METHODS: Data on demographics, disease history, resource consumption and production losses were collected from 909 patients recruited in 7 MS centres in the Czech Republic. Annual costs were estimated in the societal perspective, using 2007 unit costs. To evaluate the relationship between disability and costs, patients were stratified into those with mild (67%), moderate (27%) and severe (10%) disability using the Expanded Disability Status Scale. RESULTS: Mean total annual costs per patient were €12,272, of which 51% were direct medical costs, 4% direct non-medical costs and 45% indirect costs. The average annual costs in patients with mild, moderate and severe disability amounted to €9905, €14,064 and €22,880, respectively. CONCLUSION: The total costs of MS in the Czech Republic are estimated at €208.6 million per year. Consistent with other studies, the costs increase significantly with the severity of MS.
BACKGROUND: Information about cost of multiple sclerosis (MS) is available from a number of European countries, but no data from the Czech Republic have been published so far. OBJECTIVE: The objective of this study was to establish the cost of MS in the Czech Republic, overall and by level of disease severity. METHODS: Data on demographics, disease history, resource consumption and production losses were collected from 909 patients recruited in 7 MS centres in the Czech Republic. Annual costs were estimated in the societal perspective, using 2007 unit costs. To evaluate the relationship between disability and costs, patients were stratified into those with mild (67%), moderate (27%) and severe (10%) disability using the Expanded Disability Status Scale. RESULTS: Mean total annual costs per patient were €12,272, of which 51% were direct medical costs, 4% direct non-medical costs and 45% indirect costs. The average annual costs in patients with mild, moderate and severe disability amounted to €9905, €14,064 and €22,880, respectively. CONCLUSION: The total costs of MS in the Czech Republic are estimated at €208.6 million per year. Consistent with other studies, the costs increase significantly with the severity of MS.
Authors: Tomas Uher; Jana Blahova-Dusankova; Dana Horakova; Niels Bergsland; Michaela Tyblova; Ralph H B Benedict; Tomas Kalincik; Deepa P Ramasamy; Zdenek Seidl; Jesper Hagermeier; Manuela Vaneckova; Jan Krasensky; Eva Havrdova; Robert Zivadinov Journal: J Neurol Date: 2014-06-22 Impact factor: 4.849
Authors: Stella Célio Junqueira; Igor Dos Santos Coelho; Vicente Lieberknecht; Mauricio Peña Cunha; João B Calixto; Ana Lúcia S Rodrigues; Adair Roberto Soares Santos; Rafael Cypriano Dutra Journal: Mol Neurobiol Date: 2016-04-30 Impact factor: 5.590
Authors: Peter Rieckmann; Alexey Boyko; Diego Centonze; Alasdair Coles; Irina Elovaara; Eva Havrdová; Otto Hommes; Jacques Lelorier; Sarah A Morrow; Celia Oreja-Guevara; Nick Rijke; Sven Schippling Journal: J Neurol Date: 2012-08-31 Impact factor: 4.849
Authors: Andrius Kavaliunas; Michael Wiberg; Petter Tinghög; Anna Glaser; Hanna Gyllensten; Kristina Alexanderson; Jan Hillert Journal: PLoS One Date: 2015-12-22 Impact factor: 3.240
Authors: Tomas Uher; Jan Krasensky; Lukas Sobisek; Jana Blahova Dusankova; Zdenek Seidl; Eva Kubala Havrdova; Maria Pia Sormani; Dana Horakova; Tomas Kalincik; Manuela Vaneckova Journal: Ann Clin Transl Neurol Date: 2017-12-15 Impact factor: 4.511